Inotuzumab ozogamicin (Besponsa)

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: Antibody targeting CD22, conjugated with a cytotoxic, antitumor antibiotic (calicheamicin). Inotuzumab demonstrates a dose-dependent cytotoxicity both in vitro and in vivo. [1][2][3][4]
Route: IV
Extravasation: No information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information[1].

Diseases for which it is used

Patient drug information

History of changes in FDA indication

Also known as

  • Code name: CMC-544
  • Brand name: Besponsa

References

  1. 1.0 1.1 Inotuzumab ozogamicin (Besponsa) package insert
  2. Inotuzumab ozogamicin (Besponsa) package insert (locally hosted backup)
  3. Besponsa manufacturer's website
  4. ClinicalTrials.Gov website
  5. Inotuzumab ozogamicin (Besponsa) patient drug information (Chemocare)